ABBVIE INC. vs. Theravance Biopharma, Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| ABBV | TBPH | |
|---|---|---|
| Market Cap | $464.58 billion | $884.18 million |
| Revenue (TTM) | $64.39 billion | $104.31 million |
| Net Income (TTM) | $6.32 billion | $53.81 million |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | TBPH | |
|---|---|---|
| P/E Ratio | 72.92 | 16.87 |
| Price / Book | -78.90 | 3.05 |
| Price / Sales | 7.22 | 8.48 |
ABBV leads on 2 of 3 valuation factors.
Profitability
| ABBV | TBPH | |
|---|---|---|
| Net Margin | 9.81% | 51.58% |
| Return on Equity | -107.29% | 18.57% |
TBPH leads on 2 of 2 profitability factors.
Dividend
| ABBV | TBPH | |
|---|---|---|
| Dividend Yield | 2.68% | — |
| Payout Ratio | 195.48 | — |
ABBV and TBPH split the dividend factors evenly.
Risk & Sentiment
| ABBV | TBPH | |
|---|---|---|
| Short Interest | 0.85% | 11.71% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, TBPH overview, TBPH financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.